Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Hempdocon Jun 07, 2020 6:42pm
426 Views
Post# 31122345

RE:RE:Speculation

RE:RE:Speculation

skys1 wrote: LMM, you ask if TLT with a cure for cancer, could be worth $50, 100, or 150 p/s.
Several years ago the Chicago University's presteagious Milton Freedman School of Business did a study on what a cure for cancer would be worth on a worldwide basis.
The result was an estimate of $50 trillion. Based on that estimate, even if TLT achieved only 1% of that figure, each share of TLT would be worth roughly $2500.  
Some time ago, in the hope of the company( pre current CEO), not letting TLT go for too little in a deal, I informed Roger & Dr M of this.

 

Hey skys1...appreciate those numbers.  

I'll probably get some grief for the following....I think our PDT will be a game-changer & make us a lot of money, but as things currently stand with PDT technology, you are still limited by various factors.  These factors are not necessarily fixed or insurmountable, but certainly can affect the future bottom line.  Re: the PDT technology, issues I consider are:  higher treatment cost, reliable/adequate inventory, inherent level of complexity, adaptation of the new technology to current long-held procedures/protocols, need for wide-spread training re: it's use, the normal variation in user expertise/skill level, & overall comfort level of docs (especially the community-based/clinical docs) willing to use a new form of "procedural" ACT.  The technology is easily adaptable for accessible tumors, but for deeper/less accessible tumors, one has to utilize a more complicated/invasive approach.  Nonetheless, this approach is still exceedingly better than the alternative imo.  

IMO, the "maximum" value resides/hides in TLT's ability to perfect & utilize lower-dose "external" radiation/activation for our photosensitizer.  As for GBM or any other deep-seated tumor, if we can achieve similar superior results with an external x-ray(s) or similar form of treatment, you not only have a potential cure for solid tumors (which accounts for "90%" of cancer; the other 10% being blood cancers), you have a more immediate, simpler, more cost-friendly & more easily adaptable form of treatment....a form of treatment that would attract both university/research-based specialists as well as the community docs, the latter making up a significant majority of specialists.  

At least the above is my hope...that TLT can fine-tune & utilize this approach for future indications. If successful, this approach would boost our valuation an additional 5-10X what our current PDT would give us imo.  Looks more & more like it may come down to a matter of "degree of wealth", not flop vs some riches.  Frankly, not a bad position to be in.   Let this man dream... ; ).  Have a nice Sunday eve....

Bullboard Posts